Clinical Trial Update: Zanubritnib and Anti-MAG Neuropathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of Zanubritnib for Anti-MAG IgM-associated demyelinating polyneuropathy is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-mag Igm-associated Demyelinating Polyneuropathy

Drugs mentioned

• Zanubritnib

Snippet

Sponsor: Azienda Ospedaliera di Padova | Conditions: Anti-MAG IgM-associated Demyelinating Polyneuropathy | Phase 2 | Status: NOT_YET_RECRUITING